1. Home
  2. DLB vs ROIV Comparison

DLB vs ROIV Comparison

Compare DLB & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Dolby Laboratories

DLB

Dolby Laboratories

HOLD

Current Price

$67.61

Market Cap

6.4B

Sector

Miscellaneous

ML Signal

HOLD

Logo Roivant Sciences Ltd.

ROIV

Roivant Sciences Ltd.

HOLD

Current Price

$21.94

Market Cap

14.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DLB
ROIV
Founded
1965
2014
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Multi-Sector Companies
Biotechnology: Pharmaceutical Preparations
Sector
Miscellaneous
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.4B
14.1B
IPO Year
2005
N/A

Fundamental Metrics

Financial Performance
Metric
DLB
ROIV
Price
$67.61
$21.94
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
8
Target Price
$93.60
$21.94
AVG Volume (30 Days)
653.1K
6.5M
Earning Date
01-28-2026
11-10-2025
Dividend Yield
2.13%
N/A
EPS Growth
N/A
N/A
EPS
2.62
N/A
Revenue
$1,349,130,000.00
$20,329,000.00
Revenue This Year
$5.03
N/A
Revenue Next Year
$4.02
$376.94
P/E Ratio
$25.82
N/A
Revenue Growth
5.92
N/A
52 Week Low
$64.02
$8.73
52 Week High
$89.66
$22.45

Technical Indicators

Market Signals
Indicator
DLB
ROIV
Relative Strength Index (RSI) 53.05 68.21
Support Level $66.09 $20.14
Resistance Level $68.84 $21.48
Average True Range (ATR) 1.17 0.66
MACD 0.22 -0.02
Stochastic Oscillator 52.04 87.12

Price Performance

Historical Comparison
DLB
ROIV

About DLB Dolby Laboratories

Dolby Laboratories Inc. develops technologies that enhance audio and video capture, transmission, and playback, enabling high-quality experiences across movies, TV, music, sports, and more. The company designs and manufactures audio, imaging, accessibility, and related hardware and software mainly for cinema, including digital cinema servers and media encryption and packaging tools. It generates the majority of its revenue by licensing its technology, brand, and patents to device manufacturers and by selling cinema hardware and services. It operates as a single reportable segment, with revenue derived mainly from licensing and, to a lesser extent, from premium cinema technologies, across the United States and international markets.

About ROIV Roivant Sciences Ltd.

Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.

Share on Social Networks: